Intraoperative Cryoprecipitate Transfusion and Its Association with the Incidence of Biliary Complications after Liver Transplantation-A Retrospective Cohort Study

Shuang Liu, Junwei Fan, Xiaoliang Wang, Zijun Gong, Shuyun Wang, Li Huang, Tonghai Xing, Tao Li, Zhihai Peng, Xing Sun

Department of General Surgery, Shanghai First People’s Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

Abstract

Background: Cryoprecipitate is largely used for acquired hypofibrinogenemia in the setting of massive hemorrhage in liver transplantation (LT). However, the influence of intraoperative cryoprecipitate transfusion on biliary complications (BC) after LT has not been studied in detail.

Study Design and Methods: In a series of 356 adult patients who received their first LT, the causes of BC were retrospectively studied by multivariate logistic regression analysis. The clinical relationship between intraoperative cryoprecipitate transfusion and BC occurrence was studied through a retrospective cohort study in patients. All patients received follow-ups for one year, and, during the follow-up period, the time of BC occurrence and liver biopsies were recorded.

Results: Intraoperative cryoprecipitate transfusion (RR = 3.46, 95% CI [1.72–6.97], P < 0.001), cold ischemia time >8 h (RR = 4.24, 95% CI [2.28–7.92], P < 0.01), and high-level Child-Pugh (RR = 1.71, 95% CI [1.11–2.63], P = 0.014) are independent risk factors to predict BC after LT according to time-to-event analysis. One year BC-free survival probability of patients received intraoperative cryoprecipitate transfusions was significantly lower when compared to the group that received no cryoprecipitate (P < 0.001). Moreover, BC patients in the cryoprecipitate transfusion group owned different liver pathological feature, pathological micro-thrombus formation and cholestasis were seen more often (41.4% vs 0%, 62.1% vs 12.5%, respectively) than no cryoprecipitate transfusion group.

Conclusion: These findings suggested that intraoperative cryoprecipitate transfusion was associated with BC after LT. The mechanism of BC occurrence might involve micro-thrombus formation and immune rejection.

Introduction

Improvement of surgical techniques and immunosuppression, as well as better organ preservation have brought great improvements in success rate of liver transplantation (LT). However, postoperative biliary complications (BC) remain the weakest part of LT, and have been referred to as the “Achilles’ heel” of the procedure [1]. According to the literature, the incidence of BC after LT varies from 10% to 30% [2,3].

Although BC is a significant source of patient morbidity and mortality after LT, the mechanism of BC remains unclear and identifying risk factors of BC might give insight into the pathogenesis and reduce graft loss. Due to improvement in surgical techniques and perioperative care, the incidence of biliary anastomosis strictures and leaks decreased, however the incidence of non-anastomotic bile duct stricture became more apparent [4,5]. Previous studies in LT have found that apart from the obvious life-saving benefits, an increase in blood loss and subsequent transfusion of blood products has been associated with substantial side effects, such as increased risk of BC [6] [7].

Cryoprecipitate provided a major therapeutic advantage for patients in LT, as it does not require blood cross-matching, and is convenient to obtain. Currently, the most common indication for the use of this product is in hypofibrinogenemia in the setting of massive hemorrhage. With its increased usage in surgery, there has also been a high incidence of inappropriate use of cryoprecipitate which may range from 24%–62% [8,9]. The influence of intraoperative cryoprecipitate transfusion on BC after LT, however, has not been studied in detail.

We retrospectively reviewed our LT patients in a single center to address two issues. Firstly, whether or not intraoperative cryoprecipitate transfusion is associated with BC after LT. If this
was the case, our second objective was to detect the possible mechanism of BC occurrence. This information would allow the implementation of specific measures in high-risk patients to minimize BC occurrence.

**Materials and Methods**

**Patients**

389 patients who underwent LT at Shanghai First People’s Hospital between January 1, 2005 and December 31, 2010 were initially selected. All transplants were from cardiac death donors. We excluded Data from children (n = 1), patients who required re-transplantation (n = 23), patients with primary biliary cirrhosis (n = 7), and primary sclerosing cholangitis (n = 2), and the remaining 356 consecutive adult cases formed the analysis population.

We defined BC on the basis of a 2-fold increase of serum bilirubin greater than normal levels occurring within the first year after LT. The increased serum bilirubin levels also needed to be sustained for at least 1 week. The final diagnosis of BC was then verified through “gold standard” protocols as follows: magnetic resonance cholangiopancreatography (MRCP), endoscopic retrograde cholangio-pancreatography (ERCP), percutaneous transhepatic cholangiography (PTC), liver biopsy or intraoperative observation. The biliary anastomotic strictures and vascular anastomotic stenosis were not included in this study.

In our center, we apply cryoprecipitate transfusion to patients with fibrinogen <1.0 g/l or patients with significant coagulation problems (prothrombin time >6 s), to compensate fibrinogen or coagulation factors. We’ll stop transfusion when the thrombelastography during surgery recovers to normal range or blood exudation is significantly improved. For patients with large amount of blood loss (>2500 ml), we’ll have to transfuse blood cells which will very often lead to decreased fibrinogen (<1 g/l) and lead to cryo transfusion. For some patients with coagulation problems, even when the blood loss is less than 2500 ml, we need to do cryo transfusion to improve their coagulation function to facilitate the operation.

Clinical characteristics of these patients, including donor and recipient variables, as well as surgical factors were obtained from the China Liver Transplantation Registry (CTLR) computer database. When necessary, the original patient notes were reviewed for missing information. Risk factors determined to be meaningful predictors of BC were selected based on a review of the literature, National legislation and the ethical committee of Shanghai First People’s Hospital approved this retrospective study.

**Surgical techniques and perioperative care**

Grafts from cardiac death donors were used for all patients. The orthotopic LT technique was used for implantation. In our center, duct-to-duct reconstruction for biliary anastomosis using 7/0 prolene sutures was performed with microsurgical technique without a stent or T-tube. All surgical procedures were supervised by one of the two most experienced surgeons, who assume responsibility for the surgical team. Color Doppler sonographer was used for detecting abnormalities of the hepatic vasculature in patients with LT in the first 3 days. All patients were treated with standard immunosuppressive therapy as described elsewhere [10].

Anesthetic management during LT was performed using a common protocol previously decided by consensus. During the research period, the anesthetic protocol had little substantive change.

Follow up

Follow-ups were performed every week in the first three months, then fortnightly until six months post-transplant. Beyond this, follow-ups were performed monthly. All cases were followed routinely by our outpatient department for at least one year until the patient was lost to follow-up due to death, emigration to another district, or re-transplantation, whichever occurred first. Once serum bilirubin increased up to 2-fold of normal level, the patient was immediately admitted to hospital for further treatment.

**Statistics**

Firstly, univariate analysis of risk factors which might be associated with BC was performed. Categorical variables were compared using the Chi-squared test. Mann-Whitney u-test was used to rank data and non-normal distribution continuous variables. According to univariate analysis and previous literature, all variables might be associated with BC were subjected to stepwise logistic regression analysis with 0.1 level for entry into the model. Odds ratios and 95% confidence intervals were calculated to filter out independent risks for BC.

Using cryoprecipitate transfusions as an exposure factor, the patients with intraoperative blood product transfusions were divided into two groups. A retrospective cohort study was carried out, and baseline fractures were compared between the two groups. Intraoperative blood loss was treated as the stratified factor of the two groups given it maybe a confounding factor. MH Chi-squared test was performed when analysis combined RR. Multivariate stepwise COX regression was also performed with 0.1 level for entry into the model, to enhance the risk evidence of BC. The BC-free survival curves were calculated according to the Kaplan–Meier method and compared using the log-rank test. The time between BC occurrence and obtaining of liver biopsies from BC patients were compared to detect the possible mechanism of BC occurrence.

Continuous data are presented as mean±standard deviation. All tests were two-sided. Statistical analysis was performed using the SPSS/PC Advanced Statistics Package, Version 19.0 (SPSS, Chicago, IL). Statistical tests were assumed to have reached significance at the conventional level of 0.05.

**Results**

**Characters of BC patients and case-control analysis**

In 356 patients, a total of 40 patients had developed the BC in the first year after LT, the overall incidence of BC was 11.2% (40/356). 356 patients were divided into two groups depending on whether they had developed BC or not. Pre-, intra- and postoperative factors, blood product transfusion are summarized in **TABLE 1**. The mean requirement of cryoprecipitate for the BC group was 13.5±12.2, while the non-BC group was 5.4±2.9 U (P<0.001). The need for RBC transfusion was significantly higher in BC group (10.2±8.9) than in non-BC group (8.1±10.6, P=0.013). Univariate analysis also indicated that MELD (P=0.017) and cold ischemia time (P<0.001), were statistically significant factors between the two groups. Furthermore, according to univariate analysis and previous literature, all variables might be associated with BC were subjected to stepwise logistic regression analysis to evaluate independent risk factors associated with BC. Multivariate logistic regression analysis demonstrated that cold ischemia time >8 h (OR = 6.30, 95% CI [2.97–13.3]), intraoperative cryoprecipitate transfusion (OR = 4.23, 95% CI [1.95–9.17]), and Child-Pugh (OR = 1.79,
| Variables                  | Total | Non-BC | BC | p     |
|----------------------------|-------|--------|----|-------|
| **Age (year)**             |       |        |    |       |
| N = 356                    | 48 ± 10 | 48 ± 9 | 46 ± 10 | 0.171 |
| **Gender**                 |       |        |    |       |
| Male                       | 304 (85.4%) | 269 (85.1%) | 35 (87.5%) | 0.689 |
| Female                     | 52 (14.6%) | 47 (14.9%) | 5 (12.5%) |       |
| **Diagnosis**              |       |        |    |       |
| FHF*                       | 45 (12.6%) | 40 (12.7%) | 5 (12.5%) | 0.577 |
| Cirrhosis                  | 282 (79.2%) | 250 (79.1%) | 32 (80.0%) |       |
| Carcinoma                  | 24 (6.7%) | 22 (7.0%) | 2 (5.0%) |       |
| Others                     | 5 (1.4%) | 4 (1.3%) | 1 (2.5%) |       |
| **Child-Pugh**             |       |        |    | 0.073 |
| Grade A                    | 117 (32.9%) | 113 (35.8%) | 4 (10.0%) |       |
| Grade B                    | 142 (39.9%) | 121 (35.4%) | 21 (52.5%) |       |
| Grade C                    | 97 (27.2%) | 82 (26.9%) | 15 (37.5%) |       |
| **ABO blood group**        |       |        |    |       |
| Compatible                 | 306 (86.0%) | 272 (86.1%) | 34 (85.0%) | 0.854 |
| Incompatible               | 50 (14.0%) | 44 (13.9%) | 6 (15.0%) |       |
| **MELD**                   |       |        |    | 0.017 |
| MELD ≤ 10                  | 53 (14.9%) | 50 (15.8%) | 3 (7.5%) |       |
| 11 ≤ MELD ≤ 18             | 190 (53.4%) | 175 (55.4%) | 15 (37.5%) |       |
| 18 < MELD ≤ 24             | 20 (5.6%) | 13 (4.1%) | 7 (17.5%) |       |
| MELD ≥ 25                  | 93 (26.1%) | 78 (24.7%) | 15 (37.5%) |       |
| **Surgical factors**       |       |        |    |       |
| WIT* (min)                 | 3.4 ± 0.8 | 3.4 ± 0.8 | 3.3 ± 0.8 | 0.497 |
| CIT* (min)                 | 449 ± 111 | 440 ± 108 | 516 ± 107 | <0.001 |
| Anhepatic phase (min)      | 58 ± 10 | 58 ± 10 | 58 ± 7 | 0.578 |
| Operation time (min)       | 392 ± 95 | 389 ± 90 | 411 ± 130 | 0.851 |
| Blood loss (ml)            | 3371 ± 3419 | 3288 ± 3451 | 4023 ± 3121 | 0.025 |
| Intravenous infusion (ml)  | 5890 ± 2852 | 5893 ± 2881 | 5869 ± 2646 | 0.915 |
| **Blood products transfusion** | | | | |
| RBC (U)                    | 8.3 ± 10.4 | 8.1 ± 10.6 | 10.2 ± 8.9 | 0.013 |
| FFP* (U)                   | 2.0 ± 4.7 | 1.9 ± 4.4 | 2.8 ± 6.5 | 0.86 |
| PLT (U)                    | 0.66 ± 0.96 | 0.66 ± 0.95 | 0.65 ± 1.08 | 0.735 |
| Cryo* (U)                  | 6.3 ± 9.7 | 5.4 ± 9.0 | 13.5 ± 12.2 | <0.001 |
| Whole blood (U)            | 0.40 ± 2.07 | 0.38 ± 2.10 | 0.55 ± 1.92 | 0.172 |
| Cell saver (ml)            | 573 ± 1396 | 550 ± 1391 | 754 ± 1439 | 0.091 |
| **Postoperative factors**  |       |        |    |       |
| **Immunosuppressors**      |       |        |    |       |
| FK506 + MMF                | 305 (85.7%) | 270 (85.4%) | 35 (87.5%) | 0.595 |
| CysA + MMF                 | 43 (12.1%) | 38 (12.0%) | 5 (12.5%) |       |
| Others                     | 8 (2.2%) | 8 (2.5%) | 0 (0.0%) |       |
| Steroid                    | 195 (54.8%) | 172 (48.3%) | 23 (6.5%) | 0.713 |
| Acute rejection             | 7 (2.0%) | 6 (1.7%) | 1 (0.3%) | 0.569 |
| Chronic rejection           | 9 (2.5%) | 6 (1.7%) | 3 (0.8%) | 0.068 |

*FHF = fulminant hepatic failure; FFP = fresh frozen plasma; WIT = warm ischemia time; CIT = cold ischemia time; Cryo = cryoprecipitate.
doi:10.1371/journal.pone.0060727.t001
Retrospective cohort analysis

We analyzed the incidence of BC by a retrospective cohort study. Stratified analysis was performed depending on whether a patient had blood loss of ≤2500 ml or >2500 ml (TABLE 3). Of the 221 patients with intraoperative blood loss of less than 2500 ml, the 60 patients that received intraoperative cryoprecipitate transfusions showed a higher BC incidence than the 161 patients who had no cryoprecipitate transfused (15.0% vs. 4.97%, RR = 3.02; 95% CI [1.22–7.46]; P = 0.013). Similarly, of the 135 patients with intraoperative blood loss more than 2500 ml, the 86 patients with cryoprecipitate transfused had significantly higher BC occurrence compared to the patients who did not receive cryoprecipitate (23.3% vs. 6.12%, RR = 3.80; 95% CI [1.19–12.1]; P = 0.011). When treated blood loss as the stratified factor, the combined RR of BC (Cryo vs no-Cryo) is 3.38 (95% CI [2.28–7.92], P = 0.013). Similarly, of the 135 patients with intraoperative blood loss more than 2500 ml, the 86 patients with cryoprecipitate transfused had significantly higher BC occurrence compared to the patients who did not receive cryoprecipitate (23.3% vs. 6.12%, RR = 3.80; 95% CI [1.19–12.1]; P = 0.011). When treated blood loss as the stratified factor, the combined RR of BC (Cryo vs no-Cryo) is 3.38 (95% CI [2.28–7.92], P = 0.013). According to previous literature, BC can be classified as early or late based on whether they occur ≤90 days or >90 days after LT [11]. The analysis of 40 patients who developed BC showed that, in the group receiving cryoprecipitate transfusion, BC occurred 111±94 days after LT and 18 out of 29 patients developed late BC. In the no-cryoprecipitate transfusion group, the mean time to BC occurrence was 72±59 days (P = 0.226) and 5 in 11 patients developed late BC (P = 0.477) (TABLE 7). Neither of these parameters was significantly different, indicating that the cryoprecipitate transfusion didn’t alter the basic pathological properties of BC.

Discussion

Although BC is a major cause of graft loss and re-transplantation in patients who survive the early post-operative period after LT, the pathogenesis of BC is uncertain. In the last few years, multiple studies have found an association between intraoperative blood products transfusion and subsequently poor outcomes for...
patients who underwent LT [12–15]. Cryoprecipitate, which can control bleeding in LT through supplementation of fibrinogen and some pro-coagulant factors, was widely used in many centers. However, our study has shown that intraoperative cryoprecipitate transfusion was associated with the incidence of BC after LT. This result implies that cryoprecipitate transfusion during LTx should be performed only after careful consideration. Although our study did not provide a causal relationship between cryoprecipitate transfusion and BC, our analysis (case-control and cohort analysis) all indicated that cryoprecipitate transfusion is a significant risk

Table 4. Baseline in No-cryo group versus cryo group.

| Variables                  | Blood loss≤2500 ml | Blood loss>2500 ml |
|----------------------------|-------------------|-------------------|
|                            | Total  | Cryo | No-cryo | p    | Total  | Cryo | No-cryo | p    |
| Age(year)                  | 47.0±9.8 | 47.4±10.0 | 46.9±9.7 | 0.904 | 49.0±9.2 | 49.2±8.9 | 48.5±9.7 | 0.773 |
| Gender                     | 0.029  | 0.043 |         |      | 0.035  | 0.322 |         |      |
| Male                       | 197(91.1%) | 49(81.7%) | 148(91.9%) |   | 107(79.3%) | 68(79.1%) | 39(79.6%) |   |
| Female                     | 24(10.9%) | 11(18.7%) | 13(8.1%)  |   | 28(20.7%) | 18(30.9%) | 10(20.4%) |   |
| Diagnosis                  |         |      |         |      | 0.035  | 0.079 |         |      |
| FHF                        | 13(5.9%)  | 5(8.3%)  | 8(5.0%)  |   | 32(23.7%) | 22(16.3%) | 10(20.4%) |   |
| Cirrhosis                  | 186(84.2%) | 54(90.0%) | 132(82%)  |   | 96(71.1%) | 61(45.2%) | 35(71.4%) |   |
| Carcinoma                  | 20(9.0%)  | 0(0%)   | 20(12.4%) |   | 4(3.0%)  | 1(1.2%)  | 3(6.2%)   |   |
| Others                     | 2(0.9%)  | 1(1.7%)  | 1(0.6%)   |   | 3(2.2%)  | 2(2.3%)  | 1(2.0%)   |   |
| Child-Pugh                 | 0.001  | 0.105  |         |      | 0.198  | 0.759 |         |      |
| Grade A                    | 95(43.0%) | 16(26.7%) | 79(49.1%) |   | 22(16.3%) | 17(19.8%) | 5(10.2%)  |   |
| Grade B                    | 83(37.6%) | 26(43.3%) | 57(35.4%) |   | 59(43.7%) | 40(46.5%) | 19(38.8%) |   |
| Grade C                    | 43(19.5%) | 18(30.0%) | 25(15.5%) |   | 54(40.0%) | 29(33.7%) | 25(51.0%) |   |
| ABO blood group            |         |        |         |      | 0.041  | 0.079 |         |      |
| Compatible                 | 192(86.9%) | 55(91.7%) | 137(85.1%) | 114(84.4%) | 72(83.7%) | 42(85.7%) |   |
| Incompatible               | 29(13.1%) | 5(8.3%)  | 24 (14.9%) | 21(15.6%) | 14(16.3%) | 7(14.3%)  |   |
| MELD                       | 0.041  | 0.079  |         |      |        |        |         |      |
| MELD≤10                    | 46(20.8%) | 8(13.3%)  | 38(23.6%) | 7(5.2%) | 7(8.1%) | 0(0%)  |         |      |
| 11≤MELD≤18                 | 122(55.2%) | 31(51.7%) | 91(56.5%) | 68(50.4%) | 45(52.3%) | 23(46.9%) |   |
| 18≤MELD≤24                 | 12(5.4%)  | 3(5.0%)  | 9(5.6%)   | 8(5.9%) | 6(7.0%) | 2(4.1%) |         |      |
| MELD≥25                    | 41(18.6%) | 18(30.0%) | 23(14.3%) | 52(38.5%) | 28(32.6%) | 24(49.0%) |   |
| Surgical factors           |         |        |         |      |        |        |         |      |
| WIT (min)                  | 3.4±0.8 | 3.3±0.8 | 3.4±0.8 | 0.510 | 3.4±0.8 | 3.3±0.8 | 3.4±0.8 | 0.654 |
| CIT (min)                  | 442±113 | 445±96 | 441±119 | 0.525 | 458±107 | 452±108 | 471±106 | 0.250 |
| Anhepatic phase (min)      | 57.2±10.9 | 57.7±10.1 | 57.0±11.2 | 0.316 | 59.2±8.6 | 60.6±8.8 | 58.4±8.4 | 0.112 |
| Operation time (min)       | 360±66 | 363±72 | 359±64 | 0.803 | 445±111 | 446±122 | 443±89 | 0.547 |
| Intravenous infusion(ml)   | 4927±1359 | 4872±1402 | 4940±1347 | 0.915 | 7476±3800 | 7147±3738 | 8053±3878 | 0.079 |
| Blood products             |         |        |         |      |        |        |         |      |
| RBC(U)                     | 3.3±3.2 | 4.8±3.3 | 2.8±3.1 | <0.01 | 16.5±12.7 | 17.2±12.1 | 15.2±13.7 | 0.132 |
| FFP(U)                     | 0.8±2.1 | 1.3±2.9 | 0.6±1.6 | 0.045 | 4.0±6.7 | 4.5±7.4 | 3.1±5.3 | 0.299 |
| PLT(U)                     | 0.4±0.8 | 0.4±0.8 | 0.4±0.8 | 0.859 | 1.2±1.1 | 1.1±1.1 | 1.1±1.1 | 0.910 |
| Whole blood(U)             | 0.3±1.3 | 0.5±2.0 | 0.2±1.0 | 0.445 | 0.6±2.9 | 0.2±1.7 | 1.2±4.3 | 0.107 |
| Cell saver(ml)             | 607±1350 | 594±1348 | 628±1358 | 0.659 | 1296±2038 | 1346±2184 | 1207±1772 | 0.749 |
| Postoperative factors      |         |        |         |      |        |        |         |      |
| Immunosupressor            | 0.060  | 0.093  |         |      |        |        |         |      |
| FK506+MMF                  | 188(85.1%) | 55(91.7%) | 133(82.6%) | 117(86.7%) | 75(87.2%) | 42(85.7%) |   |
| CsA/MMF                    | 29(13.1%) | 3(5.0%)  | 26(16.2%) | 14(10.4%) | 7(8.1%) | 7(14.3%) |   |
| Others                     | 4(1.8%)  | 2(3.3%)  | 2(1.2%)  | 4(3.0%) | 4(4.7%) | 0(0%)  |   |
| Steroid                    | 118(53.4%) | 35(58.3%) | 83(51.6%) | 0.808 | 77(57.0%) | 45(52.3%) | 32(65.3%) | 0.143 |
| Acute rejection            | 4(1.8%)  | 2(3.3%)  | 0(0%)   | 0.073 | 7(5.2%) | 3(3.5%) | 4(8.2%) | 0.255 |

doi:10.1371/journal.pone.0060727.t004
factor of BC. Furthermore, it should be noted that while several baseline characters between cryo and no-cryo groups were significantly different in patients lost less than 2500 ml blood, none of these baseline characters were significantly different in patients lost more than 2500 ml blood (TABLE 4). This further supported the notion that cryoprecipitate transfusion is a significant risk factor, especially for patients lost more than 2500 ml blood.

The preparation of cryoprecipitate was first described by Judith Graham Pool in 1964 [16]. Cryoprecipitate is comprised of plasma coagulation proteins, in particular factor VIII, fibrinogen, von Willebrand factor, and Platelet microparticles (PMPs) [17]. The PMPs concentration of the cryoprecipitate has been shown to be 265-fold greater than that of the original plasma sample [18]. Isolated PMPs have been reported to activate both the extrinsic and intrinsic coagulation cascades [19], and provide a surface for thrombin formation [20]. Generally, PMPs have 50- to 100-fold higher specific procoagulant activity than activated platelets [21]. Therefore, cryoprecipitate might have a strong potential ability of promoting thrombosis. In the current study, micro-thrombus formation was observed more frequently in various sized portal area vessels in the massive cryoprecipitate transfusion group. This indicated that cryoprecipitate transfusion in LT might mediate the formation of micro-thrombosis. Large number of micro-thrombosis result in biliary microcirculation disturbance, leading to the occurrence of BC.

Small amounts of immunogenic components, such as immunoglobulin (IgG, IgM), are also present in cryoprecipitate [22]. In addition, previous research reported that PMPs are also capable of stimulating antigen-specific IgG production and activating adaptive immune cells [23]. When cryoprecipitate was transfused in patients with end-stage liver disease, the effects of these immune components were not taken into account. In the current study, liver biopsy specimens from BC patients showed that bile ducts disappeared more frequently in cryoprecipitate transfusion group. As this pathological finding was one of the typical manifestations in organ rejection, it is strongly suggested that immunogenic components existed in cryoprecipitate, played an important role in the development of BC.

Table 5. Independent risk factors associated with BC (cohort analysis).

| Variables                                  | RR*  | 95% C.I. | P     |
|--------------------------------------------|------|----------|-------|
| Cryo vs No-cryo                            | 3.46 | 1.72     | 6.97  | <0.01 |
| CIT(>8 h) vs CIT(≤8 h)                     | 4.24 | 2.28     | 7.92  | <0.01 |
| Child-Pugh increased one grade             | 1.71 | 1.11     | 2.63  | 0.014 |
| Chronic rejection vs No chronic rejection  | 3.23 | 0.99     | 10.6  | 0.052 |

*RR were derived from multivariate stepwise COX regression.
doi:10.1371/journal.pone.0060727.t005

Figure 1. Liver biopsies from BC patients. Representative histopathology images of BC patients liver biopsies. A, C are from No-cryo group and B, D are from Cryo group. In the No-cryo group, the structure of hepatic lobule was integrated, normal hepatic plates were observed, hepatic cells occurred vacular degeneration, bile duct epithelium hyperplasia and a few inflammatory cells infiltration, cholestasis was seen (A, C). The integrity of the lobular structure was loss. Intrahepatic bile ducts proliferated significantly, part of the bile duct disappeared. Bile duct epithelial deformation, atrophy, shedding. The portal area shows infiltration of lymphocytes, the intrahepatic seen varying degrees of cholestasis, micro-thrombosis was observed in various sized portal area vessels (B, D).
doi:10.1371/journal.pone.0060727.g001

Table 6. Histopathological Features of Liver Biopsies from 37 BC patients.

| Features                      | No-cryo | Cryo |
|-------------------------------|---------|------|
| Knodell HAI score             |         |      |
| Minimal (1–3)                 | 3 (37.5%)| 10 (34.5%) |
| Mild (4–6)                    | 2 (25.0%)| 12 (41.4%) |
| Moderate (7–9)                | 1 (12.5%)| 4 (13.8%) |
| Marked (10–12)                | 0 (0%)   | 2 (6.9%)  |
| Hepatic lobule structure      |         |      |
| Integrated                    | 7 (87.5%)| 8 (27.6%) |
| Disappeared                   | 1 (12.5%)| 4 (12.5%) |
| Hepatic cells Vacular degeneration | 4 (50%)| 9 (31.0%) |
| Bile duct                     |         |      |
| Epithelial hyperplasia        | 4 (50%) | 6 (20.7%) |
| Bile duct disappeared         | 1 (12.5%)| 9 (65.5%) |
| Cholestasis                   | 1 (12.5%)| 18 (61.3%) |
| Micro-thrombosis              | 0 (0%)  | 12 (41.4%) |

*Total of Knodell Histology Activity Index scores for periportal injury, parenchymal injury, and portal inflammation.
doi:10.1371/journal.pone.0060727.t006
inappropriate cryoprecipitate transfusion to replenish fibrinogen can tip this fragile balance toward thrombosis simultaneously, due to high concentration of factor VIII, and von Willebrand factor contained in cryoprecipitate [17]. Once the thrombus formation affected the blood supply of biliary tract, the incidence of BC increased significantly. Furthermore, the fibrinogen content in a unit of cryoprecipitate varied widely, ranging from 120 to 796 mg [22], this was another important cause increased the degree of difficulty to use cryoprecipitate correctly.

In the current study, cold ischemia time more than 8 h is also associated with the incidence of BC. Many previous study have showed the same conclusion [29–31]. Although this finding was not new, it strengthened a concept that minimizing cold ischemic time is essential to reduce the risk of BC. Another study stressed that high MELD score might also contribute to the risk of BC [32], but our multivariate logistic regression analysis indicated that Child-Pugh classification, not MELD score, could be associated with the risk for BC. Previous study had also stressed certain MELD components (bilirubin level and international normalized ratio) to be risk factors for BC [33]. Therefore, recipient preoperative liver function trends might have effects on BC following LT, but further confirmation is required.

Previous literature has mentioned many other risk factors that may affect the incidence of BC, such as cytomegalovirus infection [34], Rh-incompatible [35], hepatitis C virus infection [36], and hepatic artery thrombosis [37]. However, these factors were relatively minimized in this research, and the relationship between the above factors and BC could not be further determined. In addition, some studies have also proposed that T tube drainages increased the incidence of BC [38,39]. In our center, a randomized and controlled multicenter trial in 2001 reached the conclusion that T-tube drainages increased the incidence of BC [40], after which the T-tube drainages in LT had been abandoned. According to previous literature [11], we analyzed the time of BC occurrence, but there was no significant difference between cryoprecipitate transfusion group and no-cryoprecipitate transfusion group.

The limitation of the study was its retrospective nature. We did not evaluate factors that were not found for BC in the analysis. Surgical factors also contributed to the BC, but the role of these factors is becoming less significant due to the improvement of surgical techniques and perioperative care. Furthermore, we have no effective methods to carry out the assessment of the impact of surgical factors. So in this study, we excluded cases with biliary anastomosis strictures and vascular anastomotic stenosis, which were mainly caused by surgical techniques, and then the overall BC rate reduced to 11.2%.

The findings of our study suggested that cryoprecipitate transfusion, which was not noticed in other multiple analysis programs, was associated with the incidence of BC after LT. The possible risks of cryoprecipitate transfusions could be due to the complex ingredients in the product, which may cause microthrombus formation and immune rejection injury of bile ducts. To evaluate the exact role of cryoprecipitate transfusion playing in

---

**Table 7. Analysis of BC occurrence.**

| Variables      | Total | No-cryo | Cryo  | P     |
|----------------|-------|---------|-------|-------|
| N=40 N=11 N=29|
| Occurrence time| 101±79| 72±58.5 | 111±84| 0.226 |
| (days)         |       |         |       |       |
| Periods*       |       |         |       | 0.477 |
| Early BC       | 17 (42.5%) | 6 (54.5%) | 11 (37.9%) |       |
| Late BC        | 23 (57.5%) | 5 (45.5%) | 18 (62.1%) |       |

*Periods classified based on the time of BC occurrence (Early BC occurred≤90 days after the operation, Late BC occurred >90 days after the operation).

doi:10.1371/journal.pone.0060727.t007
patients with end-stage liver diseases undergone LT, more randomized, controlled multicenter trials and further research needs to be performed to develop a reasonable, standard application regarding the use of cryoprecipitate in LT. Before this research is conducted, it is necessary to be cautious while using cryoprecipitate transfusions during LT. If the use of cryoprecipitate was solely for fibrinogen supplement, it is better to adopt the protocol carried out in some European countries, where cryoprecipitate was substituted by virally inactivated fibrinogen concentrate with more standardized concentration and a safer profile (effectively reducing the risk of pathogen and immune-related complications) [41,42].

Author Contributions
Conceived and designed the experiments: XS ZP. Performed the experiments: SL JF XW. Analyzed the reagents/materials/analysis tools: LH TX. Wrote the paper: SL XS. Modified the article: XS SW.

References
1. Perrakis A, Fortsch T, Schellerer V, Hohenberger W, Muller V (2010) Biliary tract complications after orthotopic liver transplantation: still the “Achilles heel”? Transplant Proc 42: 4314–4317.
2. Wojcicki M, Milikiewicz P, Silva M (2008) Biliary tract complications after liver transplantation: a review. Dig Surg 25: 245–257.
3. Gamborg A, Carali M, Bilia A, Castelli L, Lazzaro JL, et al. (2011) Evolution of Biliary Complications After Liver Transplantation: A Single European Series. Transplant Proc 43: 745–748.
4. Heidenhain C, Pratschke J, Puhl G, Neumann U, Pascher A, et al. (2010) Incidence of and risk factors for ischemic-type biliary lesions following orthotopic liver transplantation. Transplant International 23: 14–22.
5. Chang TH, Ho MC, Wu YM, Lee PH, Hu RH (2011) Biliary complications after liver transplantation: an 18-year single-center experience. J Formos Med Assoc 110: 183–189.
6. Fusai G, Dhallsw P, Rolando N, Sabin CA, Patch D, et al. (2006) Incidence and risk factors for the development of prolonged and severe intracholedochal biliary leaks after liver transplantation. Liver Transpl 12: 1626–1633.
7. Dvorzhanski B, Biswasow V, Masei E, Dima S, Giacomoni A, et al. (2010) Biliary complications after liver transplantation: 523 consecutive cases in two centers. Hepatogastroenterology 57: 932–938.
8. Schofield WN, Rubin GL, Dean MG (2003) Appropriateness of platelet, fresh frozen plasma and cryoprecipitate transfusion in New South Wales public hospitals. Med J Aust 178: 117–121.
9. Alport EC, Callum JL, Nahirniak S, Eurich B, Hume HA (2008) Cryoprecipitate use in 25 Canadian hospitals: commonly used outside of the published guidelines. Transfusion 48: 2122–2127.
10. Kelly D, Jara P, Rodeck B, Lykivcics P, Burdeul M, et al. (2004) Tacrolimus and steroids versus ciclosporin microemulsion, steroids, and azathioprine in children undergoing liver transplantation: randomised European multicentre trial. Lancet 364: 1054–1061.
11. Atwal T, Pastrana M, Sandhu B (2012) Post-liver Transplant Biliary Complications: A Review. Transplant Proc 44: 1071–1075.
12. Pereboom IT, de Boer MT, Haagsma EB, Hendriks HG, Lisman T, et al. (2009) The impact of intraoperative transfusion of platelets and red blood cells on survival after liver transplantation. Anesth Analg 108: 32–44, table of contents.
13. Benson AB, Burton JR, Austin GL, Biggins SW, Zimmerman MA, et al. (2011) Differential effects of plasma and red blood cell transfusions on acute lung injury and infection risk following liver transplantation. Liver Transpl 17: 149–158.
14. Pool JG, Gershgold EJ, Pappenhaegen AR (1964) HIGH-POTENCY ANTI-HAEMOPHILIC FACTOR CONCENTRATE PREPARED FROM CRYO-GLOBULIN PRECIPITATE. Nature 203: 312.
15. Sparrow RL, Greening DW, Simpson RJ (2011) A protocol for the preparation of cryoprecipitate and cryodepleted plasma. Methods Mol Biol 720: 259–263.
16. George JN, Pickett EB, Heinz R (1986) Platelet membrane microparticles in blood bank fresh frozen plasma and cryoprecipitate. Blood 68: 307–309.
17. Nieuwland R, Berckmans RJ, Rotteveel-Eijkman RC, Maquelin KN, Roozen AL, et al. (2007) Platelet microparticle membranes have 50- to 100-fold higher specific phospholipid composition and cholesterol content of platelet-derived microparticle membranes compared to platelet membrane fractions. Thromb Haemost 97: 423–434.
18. Callum JL, Karkouti K, Lin Y (2009) Cryoprecipitate: the current state of knowledge. Transfus Med Rev 23: 177–181.
19. Nieuwland R, Berckmans RJ, Rotteveel-Eijkman RC, Maquelin KN, Roozen AL, et al. (2007) Practice for the use of fresh frozen plasma, cryoprecipitate, and platelets. Fresh-Frozen Plasma, Cryoprecipitate, and Platelets Administration Practice Guidelines Development Task Force of the College of American Pathologists. JAMA 271: 777–781.
20. Trippodi A, Mannucci PM (2011) The coagulopathy of chronic liver disease. N Engl J Med 365: 147–156.
21. Lim JR (2011) Chronic Liver Failure: Mechanisms and Management, First Edition. Journal of Clinical Gastroenterology 45: 914 910.1097/MCG.1090b 1013e3122e571823e1028.
22. de Vera ME, Lopez-Solis R, Dvorzhak I, Campos S, Morris W, et al. (2009) Liver transplantation using donation after cardiac death donors: long-term follow-up from a single center. Am J Transplant 9: 773–781.
23. Chan EY, Olsen IC, Kishard JA, Perkins JD, Bakhavatsalam R, et al. (2008) Intraoperative transfusion of platelets and red blood cells on survival after liver transplantation. Transplant Proc 40: 789–791.
24. de Boer MT, Christensen MC, Ammassen M, van der Hilst CS, Hendriks HG, et al. (2006) The impact of intraoperative transfusion of platelets and red blood cells on survival after liver transplantation. Anesth Analg 106: 32–44, table of contents.
25. Benson AB, Burton JR, Austin GL, Biggins SW, Zimmerman MA, et al. (2011) Differential effects of plasma and red blood cell transfusions on acute lung injury and infection risk following liver transplantation. Liver Transpl 17: 149–158.
26. Pool JG, Gershgold EJ, Pappenhaegen AR (1964) HIGH-POTENCY ANTI-HAEMOPHILIC FACTOR CONCENTRATE PREPARED FROM CRYO-GLOBULIN PRECIPITATE. Nature 203: 312.
27. Sparrow RL, Greening DW, Simpson RJ (2011) A protocol for the preparation of cryoprecipitate and cryodepleted plasma. Methods Mol Biol 720: 259–263.
28. George JN, Pickett EB, Heinz R (1986) Platelet membrane microparticles in blood bank fresh frozen plasma and cryoprecipitate. Blood 68: 307–309.
29. Nieuwland R, Berckmans RJ, Rotteveel-Eijkman RC, Maquelin KN, Roozen AL, et al. (2007) Platelet microparticle membranes have 50- to 100-fold higher specific phospholipid composition and cholesterol content of platelet-derived microparticle membranes compared to platelet membrane fractions. Thromb Haemost 97: 423–434.
30. Callum JL, Karkouti K, Lin Y (2009) Cryoprecipitate: the current state of knowledge. Transfus Med Rev 23: 177–181.
31. Sprague DL, Elzy BD, Crist SA, Waldschmidt TJ, Jensen RJ, et al. (2008) Platelet-mediated modulation of adaptive immunity: unique delivery of CD154 signal by platelet-derived membrane microparticles. Blood 111: 5026–5036.
32. (2007) Amendments and corrections to the ‘‘Transfusion Guidelines for neonates and older children’’ (BGSH, 2004a); and to the ‘‘Guidelines for the use of fresh frozen plasma, cryoprecipitate and cryosupernatant’’ (BGSH, 2004b). Br J Haematol 136: 514–516.
33. Levi M, Toth CH, Thachil J, Watson HG (2009) Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br J Haematol 145: 24–33.
34. (1994) Practice guidelines for the use of fresh frozen plasma, cryoprecipitate, and platelets. Fresh-Frozen Plasma, Cryoprecipitate, and Platelets Administration Practice Guidelines Development Task Force of the College of American Pathologists. JAMA 271: 777–781.
35. Tripodi A, Mannucci PM (2011) The coagulopathy of chronic liver disease. N Engl J Med 365: 147–156.
36. Sotiropoulos GC, Sgourakis G, Radtke A, Molmenti EP, Goumas K, et al. (2008) Platelet microparticles: a novel source of endothelial cell-derived microvesicles. Blood 112: 2754–2763.
37. Nishida S, Kato T, Muroyama R, Kato T, Shinohara K, et al. (2009) Cryoprecipitate transfusion was associated with BC

Cryoprecipitate Transfusion Was Associated with BC